Navigation Links
MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014

WILMINGTON, Delaware, September 2 /PRNewswire/ -- According to a new market research report, 'Global biosimilars Market (2009 - 2014)', published by MarketsandMarkets (, the global biosimilars market is expected to be worth US$19.4 billion by 2014, recording a CAGR of 89.1% from 2009 to 2014. The increasing demand from patients, insurers, and government agencies to reduce the costs of blockbuster biopharmaceuticals has created numerous opportunities in the global biosimilars market.

Browse more than 60 market data tables and in-depth TOC on biosimilars market. Early buyers will receive 10% customization of reports.

Currently, the biosimilars market is highly fragmented and its huge opportunities are attracting new players. Favourable regulatory developments in the biosimilars sector are expected to increase the market share and profit margins while reducing medical expenditure.

Asia's early commercialization and high absorption rate of biosimilars products made it the dominant market in 2008 with 34.1% share of the global biosimilars product market. The American market (including North America and Latin America) is expected to account for nearly 35.3% of the total revenues in 2014. The European market is also gaining momentum after the approval of its first biosimilars Omnitrope in 2006.

Recombinant non-glycosylated proteins form the largest segment in biosimilars market, with an estimated $11.5 billion by 2014. This market has a high CAGR of 87.9% from 2009 to 2014 mainly because most of the branded blockbuster biopharmaceutical drugs such as interferon, human growth hormone (Somatropin), insulin and G-CSF, belong to this class and have wide range of applications.

    Scope of the Report

    This report aims to identify and analyze biosimilars market on
    the basis of products, services, technology, and applications.

    - Biosimilars product market

    Peptides, recombinant glycosylated proteins, recombinant
    non-glycosylated proteins, and others

    - Biosimilars service market

    Contract research and manufacturing services, clinical trials

    - Biosimilars applications market

    Oncology, infectious diseases, chronic and autoimmune
    diseases, and other diseases

    - Biosimilars technology market

    Recombinant DNA technology, monoclonal antibodies technologies,
    protein sequencing, bioassay, chromatography, nuclear magnetic
    resonance, and mass spectrometry

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 60 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 40 company profiles for each of its sub-segments.

Analyst Briefings on 22nd Sep 2009 The Biotech practice at MarketsandMarkets is pleased to announce its Analyst Briefing Presentation on the Global Biosimilar market to be held on 22 Sep 2009. The briefing on the Global Biosimilar Market (2009-2014) will benefit the Active pharmaceutical ingredients (APIs) manufacturers, contract research organizations, biosimilar drug manufacturers, medical/pharma associations, research labs, healthcare service providers, regulatory authorities, and technology providers.

To register your participation, please click here biosimilar-market.asp

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)

About MarketsandMarkets

MarketsandMarkets is a research and consulting firm that publishes 120 market research reports per year. Each strategically analyzed report contains 250 pages of valuable market data, including more than 100 market data summary tables and in-depth, five-level segmentation for each of the products, services, applications, technologies, ingredients and stakeholders categories. Our reports also analyze about 200 patents, over 50 companies and micro markets that are mutually exclusive and collectively exhaustive. Browse all our 120 titles at


    Ms. Sunita
    108, West 13th Street,
    Wilmington, DE, 19801
    County of New Castle
    Tel: +1-888-989-8004

SOURCE Markets and Markets
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
2. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
3. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
4. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
5. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
6. Global Biomaterials Market Worth US$58.1 Billion by 2014
7. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
8. Elsevier Global Medical News Launches H1N1 Channel
9. NexInfo Solutions, Inc. Selected by Beckman Coulter to Design and Streamline Global Sales & Operations Planning Processes
10. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
11. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
Post Your Comments:
(Date:11/25/2015)... -- 2 nouvelles études permettent d , ... entre les souches bactériennes retrouvées dans la plaque ... . Ces recherches  ouvrent une nouvelle voie ... efficace de l,un des problèmes de santé les ...    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):